Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.
Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, Morgenstern A, Sgouros G.
Cancer Res. 2009 Dec 1;69(23):8941-8.
Epub 2009 Nov 17.

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 (213Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)
Todd Rosenblat, MD, MS, Michael R. McDevitt, PhD, Deborah A. Mulford, MD, Neeta Pandit-Taskar, MD, Mark A. Weiss, MD, Mark L. Heaney, MD, PhD, Suzanne Chanel, RN, Alfred Morgenstern, PhD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD and Joseph G. Jurcic, MD
Blood (ASH Annual Meeting Abstracts) 2008 112: Abstract 2983

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).
Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne Chanel, RN, Mark G. Frattini, MD, PhD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD and Joseph G. Jurcic, MD
Blood (ASH Annual Meeting Abstracts) 2007 110: Abstract 910

Breaking Chemoresistance and Radioresistance with [213Bi]anti-CD45 Antibodies in Leukemia Cells
Claudia Friesen, Gerhard Glatting, Bernd Koop, Klaus Schwarz, Alfred Morgenstern, Christos Apostolidis, Klaus-Michael Debatin, and Sven N. Reske
Cancer Res 2007; 67: (5). March 1, 2007

Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization.
Singh Jaggi J, Henke E, Seshan SV, Kappel BJ, Chattopadhyay D, May C, McDevitt MR, Nolan D, Mittal V, Benezra R, Scheinberg DA.
PLoS ONE. 2007 Mar 7;2:e267.
PMID: 17342201

Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after (213)Bi-radioimmunotherapy using bioluminescence imaging.
Buchhorn HM, Seidl C, Beck R, Saur D, Apostolidis C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.
Eur J Nucl Med Mol Imaging. 2007 Jan 6
PMID: 17206415

Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators.
Antczak C, Jaggi JS, LeFave CV, Curcio MJ, McDevitt MR, Scheinberg DA.
Bioconjug Chem. 2006 Nov-Dec;17(6):1551-60.
PMID: 17105236

Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys.
Jaggi JS, Seshan SV, McDevitt MR, Sgouros G, Hyjek E, Scheinberg DA.
Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1503-12. Epub 2006 Feb 28.
PMID: 16503385

Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters.
Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA.
J Am Soc Nephrol. 2005 Sep;16(9):2677-89. Epub 2005 Jun 29.
PMID: 15987754

Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.
Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.
Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7070s-7074s.
PMID: 16203804 Efforts to control the errant products of a targeted in vivo generator.Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, Scheinberg DA.
Cancer Res. 2005 Jun 1;65(11):4888-95.
PMID: 15930310 Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.
Seidl C, Schrock H, Seidenschwang S, Beck R, Schmid E, Abend M, Becker KF, Apostolidis C, Nikula TK, Kremmer E, Schwaiger M, Senekowitsch-Schmidtke R. Links
Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):274-85. Epub 2004 Oct 2.

Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.
Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK, Scheinberg DA.
Clin Cancer Res. 2004 Oct 15;10(20):6985-92.
PMID: 15501978

Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G.
Clin Cancer Res. 2004 Jul 1;10(13):4489-97.
PMID: 1524054

Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA.
J Nucl Med. 2004 Jan;45(1):129-37.
PMID: 14734685

Targeted actinium-225 in vivo generators for therapy of ovarian cancer.
Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA.
Cancer Res. 2003 Aug 15;63(16):5084-90.
PMID: 12941838

Design and synthesis of 225Ac radioimmunopharmaceuticals.
McDevitt MR, Ma D, Simon J, Frank RK, Scheinberg DA.
Appl Radiat Isot. 2002 Dec;57(6):841-7.
PMID: 12406626

Targeted alpha particle immunotherapy for myeloid leukemia.
Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA.
Blood. 2002 Aug 15;100(4):1233-9.
PMID: 12149203

Tumor therapy with targeted atomic nanogenerators..
McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. C, Molinet R.
Science. 2001 Nov 16;294(5546):1537-40.
PMID: 11711678

Cytotoxicity of 213Bi- and 225Ac-immunoconjugates.
Kaspersen FM, Bos E, Doornmalen AV, Geerlings MW, Apostolidis C, Molinet R.
Nucl Med Commun. 1995 Jun;16(6):468-76.
PMID: 7675360; UI: 95405762

The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy.
Geerlings MW, Kaspersen FM, Apostolidis C, van der Hout R.
Nucl Med Commun. 1993 Feb;14(2):121-5.
PMID: 8429990; UI: 93157017

Radionuclides for radioimmunotherapy: criteria for selection.
Geerlings MW.
Int J Biol Markers. 1993 Jul-Sep;8(3):180-6.
PMID: 8277210; UI: 94103681

Radioimmunotherapy with alpha-emitting nuclides.
McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA.
Eur J Nucl Med. 1998 Sep;25(9):1341-51. Review.
PMID: 9724387; UI: 98391728

An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation.
McDevitt MR, Finn RD, Sgouros G, Ma D, Scheinberg DA.
Appl Radiat Isot. 1999 May;50(5):895-904.
PMID: 10214708; UI: 99231323

Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, Brechbiel MW, Curcio MJ, Pippin CG, Tiffany-Jones L, Geerlings MW Sr, Apostolidis C, Molinet R, Geerlings MW Jr, Gansow OA, Scheinberg DA.
J Nucl Med. 1999 Jan;40(1):166-76.
PMID: 9935073; UI: 99131772

Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.
Sgouros G, Ballangrud AM, Jurcic JG, McDevitt MR, Humm JL, Erdi YE, Mehta BM, Finn RD, Larson SM, Scheinberg DA.
J Nucl Med. 1999 Nov;40(11):1935-46.
PMID: 10565792; UI: 20029522

Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.
McDevitt MR, Finn RD, Ma D, Larson SM, Scheinberg DA.
J Nucl Med. 1999 Oct;40(10):1722-7.
PMID: 10520715; UI: 99449025

In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH. Cancer Res. 2000 Sep 15;60(18):5237-43.
PMID: 11016653; UI: 20468868

An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geerlings MW Jr, Lee M, Brechbiel MW, Bander NH, Cordon-Cardo C, Scheinberg DA. Cancer Res. 2000 Nov 1;60(21):6095-100. [MEDLINE record in process]
PMID: 11085533; UI: 20535983

<BACK TO TOP >